Ritu Salani, MD

Ritu Salani, MD, offers advice for community oncologists treating patients with cervical cancer and discusses the future directions of the treatment landscape.

A gynecologic oncologist discusses second-line treatment options for patients with recurrent or metastatic cervical cancer, and provides insights on toxicity management.

An overview of first-line treatment options and immune checkpoint inhibitors in metastatic cervical cancer.

Ritu Salani, MD, offers clinical insights on the role of biomarker testing in treating cervical cancer.

An expert gynecologic oncologist reviews the biology of cervical cancer and discusses how HPV vaccination is increasingly playing a role in prevention.

Ritu Salani, MD, presents the case of a patient with cervical cancer and describes the typical disease presentation and risk factors.

Closing out her discussion on novel therapeutics in endometrial cancer, Ritu Salani, MD, MBA, shares excitement for ongoing evolutions within the treatment landscape.

Expert Ritu Salani, MD, MBA, reviews data from TROPiCS-03 and considers the potential role for antibody drug conjugates in patients with advanced endometrial cancer.

A brief review of clinical trial data from RAINBO and GY020, which tested adjuvant immunotherapy following radiation in patients with endometrial cancer.

Focused discussion on single-agent immunotherapy in patients with advanced endometrial cancer following data from the PHAEDRA and DOMENICA clinical trials.

Expert perspectives on the RUBY and GY018 trials, which tested dostarlimab and pembrolizumab, respectively, in combination with chemotherapy in patients with advanced or recurrent endometrial cancer.

Closing out her discussion on the management of recurrent endometrial cancer, Ritu Salani, MD, MBA, shares clinical pearls amidst the shifting treatment paradigm.

A focused review of clinical trial data that inform the use of immune checkpoint inhibition in the setting of recurrent endometrial cancer.

An expert gynecologic oncologist shares her perspective on treatment options available to patients in the first- and second-line settings of endometrial cancer.

Opening her discussion on a patient case of recurrent endometrial cancer, Ritu Salani, MD, MBA, highlights the evolving role of molecular testing in this setting.